Estimating Australian Hospitalization Ratios and Costs for Wildtype SARS-CoV-2 in 2020CURRENT PROBLEMS IN CARDIOLOGYIF3.32023-11-010OA
Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease PhaseHEPATOLOGYIF15.82021-04-2910OAAI
Perceptions of vaccine preventable diseases in Australian healthcare: focus on pertussisHUMAN VACCINES & IMMUNOTHERAPEUTICSIF3.52020-07-2210OAAI
Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccineHUMAN VACCINES & IMMUNOTHERAPEUTICSIF3.52020-06-238OAAI
Australian perceptions of pertussis and vaccine preventable disease in the setting of asthma and COPDEUROPEAN RESPIRATORY JOURNALIF212019-11-210PRE
Hepatitis B splice variants are strongly associated with and are indeed predictive of hepatocellular carcinomaJOURNAL OF HEPATOLOGYIF332018-04-013PREAI
HBeAg levels at week 24 predict response to 8years of tenofovir in HBeAg-positive chronic hepatitis B patientsALIMENTARY PHARMACOLOGY & THERAPEUTICSIF6.72017-10-114OAAI
On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHBJOURNAL OF HEPATOLOGYIF332017-01-010PREAI
Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversityAIDSIF3.12016-06-1916PREAI
THE PRESENCE OF BCP/PC VARIANTS REDUCES THE RATE OF HBSAG LOSS AMONG HBEAG-POSITIVE CHB PATIENTS TREATED WITH LONG-TERM TENOFOVIR DF THERAPYJOURNAL OF HEPATOLOGYIF332016-01-010PREAI
HBV VARIANTS PRESENT IN TREATMENT NAIVE PATIENTS CAN PREDICT RESPONSE TO NA THERAPY IN IMMUNE CLEARANCE DISEASEJOURNAL OF HEPATOLOGYIF332015-04-011PREAI
GENOTYPE SPECIFIC VARIATION IN THE BASAL CORE PROMOTER AND PRE CORE REGIONS IMPACTS HBeAg LEVELS DURING IMMUNE CLEARANCE DISEASEJOURNAL OF HEPATOLOGYIF332015-04-010PREAI
EFFECT OF TENOFOVIR ON KEY HEPATITIS B VIRUS MARKERS IN PREGNANT WOMEN DURING THE THIRD TRIMESTER AND POSTPARTUMJOURNAL OF HEPATOLOGYIF332015-04-010PREAI
QUANTITATIVE MEASUREMENTS OF MUTATIONS IN BASAL CORE PROMOTOR REGION SUGGEST A LOSS OF IMMUNE TOLERANCE IN HBeAg POSITIVE CHRONIC HEPATITIS B INFECTIONSJOURNAL OF HEPATOLOGYIF332015-04-010PREAI
Downregulation of Interleukin-18-Mediated Cell Signaling and Interferon Gamma Expression by the Hepatitis B Virus e AntigenJOURNAL OF VIROLOGYIF3.82014-09-1552OA
RECLASSIFICATION OF IMMUNOTOLERANT CHRONIC HEPATITIS B INFECTION; DETECTION OF HBV VARIANTS WITH IMPLICATIONS FOR HBVDNA, HBsAg AND HBeAg LEVELSJOURNAL OF HEPATOLOGYIF332014-04-011PREAI
HBeAg LEVELS DIFFER ACCORDING TO HBV GENOTYPE IN IMMUNE CLEARANCE DISEASEJOURNAL OF HEPATOLOGYIF332014-04-010PREAI
NUCLEOS(T)IDE ANALOGUE (NA) THERAPY FOR PERSONS IN THE IMMUNOTOLERANT PHASE OF CHB IS ASSOCIATED WITH SIGNIFICANT DECLINE IN HBeAg AND HBsAg LEVELSJOURNAL OF HEPATOLOGYIF332014-04-010PREAI
Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinomaJOURNAL OF HEPATOLOGYIF332013-11-0160PREAI
Human leucocyte antigen-defined microchimerism early post-transplant does not predict for stable lung allograft function移植后早期人类白细胞抗原定义的微嵌合体不能预测稳定的肺同种异体移植功能CLINICAL AND EXPERIMENTAL IMMUNOLOGYIF3.82013-04-184OA